Merck & Co – known as MSD outside of the US and Canada – has shared positive results from a late-stage trial of a Keytruda ...

Since Ipsen arrived in the UK in 1981, we have sought to build on our legacy of improving outcomes for people living with diseases in areas of high unmet need. Over that period, the UK life sciences ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...

Our cover story this month features John Forni, Country Medical Director at Sanofi UK & Ireland, and I spoke to John about the escalating challenges of treating chronic obstructive pulmonary disease ...

Eli Lilly has announced a $3bn expansion to the US manufacturing facility that it acquired from Nexus Pharmaceuticals earlier ...

Cuttsy+Cuttsy proudly announces their Gold Medal achievement from EcoVadis for 2024, placing them among the top 5% of ...

GSK and Duality Biologics have entered into an exclusive option agreement worth over $1bn for DualityBio’s preclinical ...

Merck & Co – known as MSD outside of the US and Canada – and Ridgeback Biotherapeutics have initiated a late-stage study to ...

GSK and Rgenta Therapeutics have partnered to develop RNA-targeting small molecule splice modulators for disease areas ...

Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) ...

Did you know we offer a suite of education and training options? Our workshops, insight sessions, and training help Pharma ...

Johnson & Johnson (J&J) has shared positive data from a late-stage study of its subcutaneous CD38-directed antibody Darzalex ...